Optimized oral treatment ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04332276 (ClinicalTrials.gov)	September 18, 2020	25/3/2020	Dopaminergic restauratIon by intraVEntriculaire Administration	A New Concept of Continuous Dopaminergic Stimulation by Cerebroventricular Administration of A-dopamine (Dopamine Stored in Anaerobia) for Severe Motor Fluctuations in Parkinson's Disease?	Parkinson Disease	Drug: A-dopamine;Drug: optimized oral treatment	University Hospital, Lille	InBrain Pharma	Recruiting	45 Years	75 Years	All	20	Phase 1/Phase 2	France
2	EUCTR2020-000155-12-FR (EUCTR)	12/05/2020	14/01/2020	Dopaminergic restauratIon controlled by intraventriculaire administration	A new concept of continuous dopaminergic stimulation by cerebroventricular administration of A-dopamine (dopamine stored in anaerobia) for severe motor fluctuations in Parkinson’s disease? - DIVE-I	Proof of concept study: prospective, monocentric, controlled randomized study according a cross over design with 2 groups: cerebroventricular administration of A-dopamine versus optimized oral treatment in patients with Parkinson’s disease at the stage of severe motor complications related with oral L-dopa (fluctuations and dyskinesia). ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Product Name: Solution de chlorhydrate de dopamine anaérobie Product Code: A-dopamine	InBrain Pharma SAS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 1;Phase 2	France